Literature DB >> 7572642

Recurrence of primary (AL) amyloidosis in a transplanted heart with four-year survival.

S Dubrey1, R W Simms, M Skinner, R H Falk.   

Abstract

Cardiac amyloidosis has a poor prognosis, with a median survival of approximately 6 months once symptoms develop. This patient had a markedly improved quality of life with cardiac transplantation. We would suggest that with refinement of pretransplant chemotherapy, prolonged survival may be possible in carefully selected cases.

Entities:  

Mesh：

Year:  1995        PMID： 7572642     DOI： 10.1016/s0002-9149(99)80214-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  6 in total

1.  Restrictive Cardiomyopathy.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-10

2.  Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience.

Authors:  Martha Grogan; Morie Gertz; Arleigh McCurdy; Lindsey Roeker; Robert Kyle; Sudhir Kushwaha; Richard Daly; Joseph Dearani; Richard Rodeheffer; Robert Frantz; Martha Lacy; Suzanne Hayman; Christopher McGregor; Brooks Edwards; Angela Dispenzieri
Journal:  World J Transplant       Date:  2016-06-24

3.  Long term results of heart transplantation in patients with amyloid heart disease.

Authors:  S W Dubrey; M M Burke; A Khaghani; P N Hawkins; M H Yacoub; N R Banner
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

Review 4.  Deposition-associated diseases related with a monoclonal compound.

Authors:  M J Molina-Garrido; C Guillén-Ponce; A Mora; M Guirado-Risueño; M A Molina; M J Molina; A Carrato
Journal:  Clin Transl Oncol       Date:  2007-12       Impact factor: 3.405

Review 5.  Primary systemic amyloidosis.

Authors:  Morie A Gertz; S Vincent Rajkumar
Journal:  Curr Treat Options Oncol       Date:  2002-06

Review 6.  State-of-the-art review on management of end-stage heart failure in amyloidosis: transplant and beyond.

Authors:  Salil Kumar; Daniel Li; Denny Joseph; Barry Trachtenberg
Journal:  Heart Fail Rev       Date:  2022-02-03       Impact factor: 4.654
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.